Neal D. Shore, MD, discusses the US commercial launch of the PSMA PET imaging agent piflufolastat F 18 (Pylarify). Lantheus, the developer of piflufolastat F 18, selected oncology provider GenesisCare to administer the first commercially available dose of the agent.
Piflufolastat F 18 was approved by the FDA in May 2021 based on findings from the CONDOR and OSPREY studies. In the CONDOR study, 63.9% of men with biochemically recurrent prostate cancer who had no evidence of disease on standard-of-care imaging had a change in intended management after their piflufolastat F 18 scan.
Shore is US chief medical officer of Surgery and Urology, GenesisCare, and medical director of the Carolina Urologic Research Center.